Kefort (Ibandronic Acid)

Ibandronic acid binds to bone mineral surfaces and is taken up by osteoclasts during bone resorption. Inside these cells it blocks the enzyme farnesyl pyrophosphate synthase, which is essential for osteoclast function, leading to decreased bone breakdown and a net gain in bone strength.

The dosing regimen for Kefort is determined by the prescribing clinician based on the patient’s medical condition, renal function, and other individual factors. The prescriber will specify the exact dose, frequency, and duration of therapy.

Kefort is generally not recommended for use during pregnancy or while breastfeeding unless the potential benefits outweigh the risks. Women who are pregnant, planning to become pregnant, or nursing should discuss alternative treatment options with their healthcare provider.

To order Kefort, submit an enquiry on the product page at gnhindia.com, providing the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then replies with pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Kefort (ibandronic acid) is a potent bisphosphonate similar to alendronate or risedronate but is often administered less frequently (e.g., monthly). Compared with other classes such as selective estrogen receptor modulators or monoclonal antibodies, bisphosphonates like Kefort have a well‑established safety profile and are effective at reducing vertebral and non‑vertebral fractures.

Kefort tablets should be stored at ambient temperature, below 25 °C, in the original blister pack to protect them from moisture and light. Keep the medication out of reach of children and do not use if the packaging is damaged.

Kefort is taken orally, usually with a full glass of water on an empty stomach. Patients should remain upright for at least 30 minutes after ingestion and avoid eating, drinking, or taking other medications during that time to ensure optimal absorption.

Serious risks include osteonecrosis of the jaw, atypical femoral fractures, severe hypersensitivity reactions, and acute renal impairment. Patients should promptly report persistent jaw pain, unexplained thigh or groin pain, signs of an allergic reaction, or sudden changes in kidney function.

Kefort is contraindicated in individuals with severe renal impairment, known hypersensitivity to ibandronic acid or other bisphosphonates, and patients who have had recent major dental surgery or jaw trauma. It should also be avoided in pregnant or nursing women unless specifically advised by a physician.